Home  /  Resource Library  /  Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis

Tumor Lysis Syndrome Risk in Burkitt Lymphoma Versus Mantle Cell Lymphoma During Alkylating Therapy: A Propensity-Matched TriNetX Comparative Outcome Analysis

Study investigated rates of tumour lysis syndrome in Burkitt and MCL.